Nicox reported net revenue of 3.3 million euros in the fourth quarter of 2018 compared with net revenue of 2.3 million euros in 2017’s fourth quarter.
The total includes an upfront payment from Ocumension for NCX 470 for the Chinese market and royalties on sales of Vyzulta (latanoprostene bunod ophthalmic solution 0.024%) by the company’s global partner Bausch + Lomb, according to a press release.
In the fourth quarter, Vyzulta prescriptions in the U.S. rose by 47% compared with the third quarter of the year.
The company’s year-end net revenue (Read more...)
Uncategorized